KRAS and cancer: In the future, algorithms including all available prognostic values—genetic mutation, in this respect KRAS mutation as a factor for efficacy of hormonal therapy; ultrasound features (depth of myometrial invasion); and clinical characteristics (age, concomitant disease, BMI)—might lead to the individualized management of patients with adenomyosis, with a possible malignant transformation of adenomyosis into cancer.